Patients with moderate pain (52%) received dipyridam 19 mg/kg q 6 hours (86%) and tramadol 1.1 mg/kg q 4–8 h (95%) and morphine 0.1 mg/kg every 3–6 hours (53%).

Patients with severe pain (37.5%) received dipyridam 19 mg/kg q 6 hours (93%) and tramadol 1.2 mg/kg q 4–8 h (93%) and morphine 0.1 mg/kg every 3–6 hours (60%).

Patients who received tramadol i.v. in intervals over 6 hours (12.5%), and received morphine i.v.in intervals over 4 hours (10%) had moderate and intense pain.

Conclusions Tramadol and morphine i.v. should not be administered in intervals longer than 6 hours for tramadol and 4 hours for morphine due to its half life. (Tramadol T1/2:2.5.5.h and morphine T1/2: 2 hours).

Since dipyridone inhibits cicloxygenase and reduces tromboxane levels in platelets, antiaggregating effect should be evaluated in sickle cell disease patients.

1532  HEPATITIS A IN PEDIATRIC WARD (EXPERIENCE IN THE PEDIATRIC SERVICE OF CHU OF BATNA)

ND Righi, S Brahmi, H Zerguine, H Sahani, S Tebbal. CHU Benfils Touhami, Université de Batna, Park Mokrane, Algeria

Introduction Hepatitis A is a real public health problem worldwide: 273 confirmed cases in Algeria in 2010. She is responsible for 10–50% of hepatitis in adults and 70–90% in children.

Objectives To determine the frequency and severity of hepatitis A.

Materials and Methods A retrospective study done on the records of patients hospitalized for complicated form of hepatitis A over a period of 02 years (2009–2010). 28 patients hospitalized for complicated forms: signs of liver failure.

Results Incidence: 1.15%.

Age group affected is between 5–10 years with a female predominance.

In Algeria the transmission is the predominant waterborne, mostly occurring in winter. Fever, vomiting and asthenia constitute 68.74% of the reasons for consultation. The average AST, ALT was elevated 100 times normal.

Conclusion Hepatitis A is very common in Algeria in connection with a water-borne and the majority of cases are asymptomatic and almost at the age of 18 years 95% of patients develop antibodies.

1533  EPIDEMIOLOGICAL PROFILE OF URINARY TRACT INFECTION IN PEDIATRIC WARD (EXPERIENCE OF A PEDIATRIC SERVICE OF THE UNIVERSITY HOSPITAL OF BATNA)

HD Zerguine, S Brahmi, S Taleb, S Tebbal. Sciences Médicales de Batna, CHU de Batna, Logements, Algeria

Introduction Urinary tract infection (UTI) is one of the most common infectious attacks in children. Pediatrics significant problem for many reasons: its incidence, the polymorphism of clinical manifestations, its potential severity (renal scarring), the possibility of revealing a uropathy.

Objective Evaluate the incidence, morbidity and long-term acute (hypertension, renal failure), the proportion of bacterial strains involved and how they supported.

Materials and Methods Retrospective study done on the records of patients hospitalized in pediatric ward from 01–01–2009 until 31–12–2009.

130 patients were the subject of this study.

Results Incidence: 4.64%.

Frequenly females (sex ratio 0.68). The age group most affected is from 30 days to 05 years (range 30 d and 15).

Fever was noted in 110 patients, 44 patients complained of urinary symptoms. The gross hematuria was observed in 07 patients. Leukocytosis was present in 84.62% of cases; an ESR above 30 in 14.4% of patients. CRP was positive in 65.38% of patients.

E coli in 22.38% cases, followed in descending order of pneumo- niedades klebsiella, pseudomonas aeroginosa, Proteus, enterococcus. Ultrasound renal disease 17.16% (7.58% urétérohydronéphrose). The UCR pathological in 9.70% (6% RVU).

Pathological IVU 5.22% (3% urétérohydronéphrose).

Conclusion This study confirmed the frequency of UTI in a pediatric setting. However, great efforts are still needed to better support her.

Better knowledge of bacteriology: prevalence of germs, sero-typing, with ATB resistance;

The long-term prophylactic treatment of UI also remains to be defined.

Supprimer Répondre Faire suivre Déplacer Imprimer Actions Suiitvent Précédent.
Background and Aims The availability of appropriate medicines for pediatric patients remains a challenge in any Health System. To evaluate the extent of this limitation in Portugal, the INFARMEDES, I.P., conducted the present study aiming at 1) knowing which extemporaneous formulations were prepared/used in hospital settings and 2) identifying which of these have a liquid formulation medicine available in Portugal, EU or USA.

Methods A cross sectional study was performed in nine Hospitals in Portugal regarding the collection of 2010 data on the use and production of extemporaneous formulations. The information was gathered trough a questionnaire. Data analysis was restricted to medicines with more than 1000 formulations prepared or prescribed to more than 100 patients.

Results Thirty three medicines met the defined criteria. They were included in groups A and C of the ATC classification (Alimentary Tract and Metabolism and Cardiovascular System) with 8/33 (24.24%) each, followed by Anti-infectives for Systemic Use and Nervous System with 5/33 (15.15%) each. It was realized that 20 (75.76%) have a licensed oral liquid formulation either in Portugal, EU or USA. In Portugal 7 (21.21%) have or had a market authorization no longer available due to industrial ending. In addition, different hospitals prepare the same medicine in distinct formulations.

Conclusions The results confirmed the need to widen clinical studies of ocular drugs in paediatrics, not only concerning limited controlled trials but also their rational use.

1536 PHARMACOEPIDEMIOLOGY OF OCULAR PRESCRIPTIONS IN PAEDIATRIC OUTPATIENTS IN PORDENONE PROVINCE
doi:10.1136/archdischild-2012-302724.1536
G Montanari, P Schiuladi. Clinical Research Department, FIMP Friuli Venezia Giulia, Sacile, Italy

Background and Aims The use of ocular drugs in paediatrics is often "off-label", concerning both safety in relation to the age and efficacy. For this reason we have deemed it necessary to examine prescribing habits of family paediatricians (pdf).

Methods Each pdf of Pordenone province (315.323 inhabitants) was sent a questionnaire where it was requested to list the ocular drugs usually prescribed, why they were prescribed and any side effect observed. They were also requested to confirm any use of dietary supplements or other medical devices.

Results All 35 pdf (34.440 children, aged 0–14 years) filled in the questionnaire. The most commonly prescribed drugs were antibiotics, anti-histamine agents and mast cell stabilizers for bacterial and allergic conjunctivitis. Only topical drugs were used. Children affected by serious ocular diseases were referred to ophthalmologists and of these only four assumed drugs for vernal conjunctivitis and glaucoma (cyclosporine, timolol, dorzolamide and bimatoprost). Only minor adverse reactions (conjunctival hyperaemia, lid swelling) were found, even if potentially dangerous drug associations are still used (i.e. associations with steroids and/or sympathomimetic decongestants). No dietary supplements or medical devices were prescribed.

Conclusions Many ocular drugs lack reliable proof of efficacy and safety in paediatrics but fortunately their use outside the hospital seems limited. Nevertheless their use can probably be improved. Our research confirms the need to widen clinical studies of ocular drugs in paediatrics, not only concerning limited controlled trials but also their rational use.

1537 EFFECTIVENESS OF MELATONIN IN TREATING SLEEP PROBLEMS IN CHILDREN - PARENT SATISFACTION SURVEY
doi:10.1136/archdischild-2012-302724.1537
1A Gupta, 2C Varthaman. 1Addenbrookes Hospital, Cambridge, 2Bedford Community Paediatrics, Bedford, UK

Background and Aim Melatonin is not licensed for children in UK. Limited evidence is available about its efficacy and safety. We assessed parents’ satisfaction with melatonin for treatment of sleep problems in children.

Methods 27 children who were prescribed melatonin by community paediatricians at Bedford, UK were randomly selected. Structured questionnaire was given to their parents.

Results
1. Parents’ overall assessment of response to melatonin treatment - Good (63%), Average (33%), Poor (4%).
2. Analysis of age group of children with good response: 1–5 years (3 out of 3 children i.e 100%), 6–10 years (7/12 i.e 58%), 11–16 years (7/10 i.e 70%), Over 16 years (0/2 i.e 0%).
3. Effect on sleep when melatonin was stopped (in 18 children) - worsening (72%), same (28%), improvement (0%).
4. All the children had associated problems - 81% behavioural (autism, ADHD), 19% structural/chromosomal. 41% were in mainstream school, 55% special need school and 4% left school.
5. Improvement in behaviour secondary to improvement in sleep - yes (26%), No (74%).
6. Improvement in quality of life of parents secondary to fewer interruptions to their sleep - Yes (77%), No (23%).
7. Only 1 child had side effects including headache, confusion and tiredness while taking melatonin. He was on high dose of 10 mg/day.

Conclusion Most parents reported improvement in sleep of their children after being started on melatonin. Also majority reported better quality of life due to less interruption to their sleep.

1538 USE OF PROPRANOLOL FOR TREATING EPISTAXIS - FIRST EXPERIENCES
doi:10.1136/archdischild-2012-302724.1538
1B Bjelakovic, 2M Bojanovic, 3S Lukic, 4G Kostic, 5N Zivkovic, 6Vukomanovic, 7S Prijic. 1,2Marinovick. 1Clinic of Pediatrics, Clinical Center, Medical Faculty, University of Nis; 2Clinic of Otorhinolaryngology, Clinical Center, Medical Faculty, University of Nis; 3Clinic of Neurology, Clinical Center, Medical Faculty, University of Nis; 4Institute of Pathology, Medical Faculty, University of Nis; 5Mother and Child Health Institute, 'Dr Vukan Cupic', Belgrade; 6Clinic of Otorhinolaryngology, Clinical Center, Nis, Serbia

Beta blockers are considered to be the most common prescribed class of drugs in treating cardiovascular diseases. However they are very useful in treating other conditions, such as migraine, glaucoma, hemangiomas, cirrhosis, etc.

We hypothesized that some beta blockers characteristics including their negative inotropic, peripheral vasoconstrictor and antiangiogenic effects might be potentially useful in the management of children with epistaxis.

To test this we sought to determine the efficacy of propranolol as a second line therapy in children with recurrent primary epistaxis, resistant to conventional management. From June 2010 to October 2011, a total of six children with this features were seen a our institution.

The overall effectiveness of propranolol for terminating epistaxis, given in dosage of 1.5–2 mg/kg/day, three times a day, was successful in all six treated children (100 % efficacy) becoming evident within 24 hours after the after the initiation of treatment. The epistaxis free interval period lasted at least one year, in five children and 43 days in one children.

Based on our first experiences with propranol, we believe this drug could be promising treatment option for children with primary epistaxis.

1539 LENGTH OF HOSPITAL STAY IN CHILDREN WITH ACUTE VIRAL PNEUMONIA TREATED WITH CORTICOSTEROIDS, A RETROSPECTIVE STUDY
doi:10.1136/archdischild-2012-302724.1539
1A Gupta, 2C Varthaman. 1Addenbrookes Hospital, Cambridge, 2Bedford Community Paediatrics, Bedford, UK

Background and Aim Melatonin is not licensed for children in UK. Limited evidence is available about its efficacy and safety. We assessed parents’ satisfaction with melatonin for treatment of sleep problems in children.

Methods 27 children who were prescribed melatonin by community paediatricians at Bedford, UK were randomly selected. Structured questionnaire was given to their parents.

Results
1. Parents’ overall assessment of response to melatonin treatment - Good (63%), Average (33%), Poor (4%).
2. Analysis of age group of children with good response: 1–5 years (3 out of 3 children i.e 100%), 6–10 years (7/12 i.e 58%), 11–16 years (7/10 i.e 70%), Over 16 years (0/2 i.e 0%).
3. Effect on sleep when melatonin was stopped (in 18 children) - worsening (72%), same (28%), improvement (0%).
4. All the children had associated problems - 81% behavioural (autism, ADHD), 19% structural/chromosomal. 41% were in mainstream school, 55% special need school and 4% left school.
5. Improvement in behaviour secondary to improvement in sleep - yes (26%), No (74%).
6. Improvement in quality of life of parents secondary to fewer interruptions to their sleep - Yes (77%), No (23%).
7. Only 1 child had side effects including headache, confusion and tiredness while taking melatonin. He was on high dose of 10 mg/day.

Conclusion Most parents reported improvement in sleep of their children after being started on melatonin. Also majority reported better quality of life due to less interruption to their sleep.

1538 USE OF PROPRANOLOL FOR TREATING EPISTAXIS - FIRST EXPERIENCES
doi:10.1136/archdischild-2012-302724.1538
1B Bjelakovic, 2M Bojanovic, 3S Lukic, 4G Kostic, 5N Zivkovic, 6Vukomanovic, 7S Prijic. 1,2Marinovick. 1Clinic of Pediatrics, Clinical Center, Medical Faculty, University of Nis; 2Clinic of Otorhinolaryngology, Clinical Center, Medical Faculty, University of Nis; 3Clinic of Neurology, Clinical Center, Medical Faculty, University of Nis; 4Institute of Pathology, Medical Faculty, University of Nis; 5Mother and Child Health Institute, 'Dr Vukan Cupic', Belgrade; 6Clinic of Otorhinolaryngology, Clinical Center, Nis, Serbia

Beta blockers are considered to be the most common prescribed class of drugs in treating cardiovascular diseases. However they are very useful in treating other conditions, such as migraine, glaucoma, hemangiomas, cirrhosis, etc.

We hypothesized that some beta blockers characteristics including their negative inotropic, peripheral vasoconstrictor and antiangiogenic effects might be potentially useful in the management of children with epistaxis.

To test this we sought to determine the efficacy of propranolol as a second line therapy in children with recurrent primary epistaxis, resistant to conventional management. From June 2010 to October 2011, a total of six children with this features were seen a our institution.

The overall effectiveness of propranolol for terminating epistaxis, given in dosage of 1.5–2 mg/kg/day, three times a day, was successful in all six treated children (100 % efficacy) becoming evident within 24 hours after the after the initiation of treatment. The epistaxis free interval period lasted at least one year, in five children and 43 days in one children.

Based on our first experiences with propranol, we believe this drug could be promising treatment option for children with primary epistaxis.